Applications
The core immunoassay technologies developed by PalindromX have applications in the following areas:
PalindromX has licensed patents (from the University of Liverpool) that protect their unique immuno-PCR approach from the University of Liverpool:
|
·
|
Immuno-PCR Method, WO03/048388, now at National Phase in USA and Europe
|
|
·
|
Immuno-PCR Method, application number PCT/GB04/000193 due to enter National Phase in July 2005
|
|
·
|
DNA Vaccination, WO 03/048371 A3, now at National Phase in USA and Europe
|
Key Features Benefits
|
·
|
Orders of magnitude reduction in assay Limits Of Detection Improvement in diagnostic efficiency
|
|
·
|
Increased sensitivity within same cost per test range No increased costs for improved technology
|
|
·
|
Multi-analyte capability (more results in a given time) Increased sample turnover/reduced cost per test
|
|
·
|
Compatible with current laboratory automation systems Reduced costs of implementation
|
To see an overview of how PalindromX immunoassay technology works, click this link
Way Forward
PalindromX has secured funding from Merseyside Special Investments Fund/Liverpool Ventures to deliver the following:
|
·
|
Recruit a suitably qualified post-doctoral researcher to continue laboratory studies (Completed, October 2007)
|
|
·
|
Finalise “proof of concept” studies in serum/plasma for two commercially valuable analytes (Expected, April 2008)
|
|
·
|
Use data achieved to enter license negotiations for clinical diagnostic and other applications (Expected, Q2, 2008)
|
|
·
|
Develop multi-analyte capability to proof of concept stage (Expected, Q2, 2008)
|
|
·
|
Develop existing complementary Intellectual Property relating to DNA-based antibody production (2008)
|
|
·
|
Seek partnerships for development in other application areas (2008)
|
To download information on PalindromX immunoassay technology, click this link
Introduction: In a number of important areas of clinical medicine, existing limits of detection and sensitivity parameters restrict the ability of clinicians to make early, accurate diagnoses and assess efficacy of increasingly expensive treatments. There is a general IVD industry desire to lower limits of detection, improve assay sensitivity and also to make simultaneous multi-analyte measurements during one measurement cycle. It is in these key areas that PalindromX have targeted their core technology developments.
